CA2922851C - Sodium channel modulators for the treatment of pain and diabetes - Google Patents

Sodium channel modulators for the treatment of pain and diabetes Download PDF

Info

Publication number
CA2922851C
CA2922851C CA2922851A CA2922851A CA2922851C CA 2922851 C CA2922851 C CA 2922851C CA 2922851 A CA2922851 A CA 2922851A CA 2922851 A CA2922851 A CA 2922851A CA 2922851 C CA2922851 C CA 2922851C
Authority
CA
Canada
Prior art keywords
chloro
compound
formula
pain
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2922851A
Other languages
English (en)
French (fr)
Other versions
CA2922851A1 (en
Inventor
Olga BABICH
Tina Garyantes
Robert Z. Luo
David J. Palling
Srinivasan P. Venkatachalan
Yanlin WANG-FISCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromocell Corp
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of CA2922851A1 publication Critical patent/CA2922851A1/en
Application granted granted Critical
Publication of CA2922851C publication Critical patent/CA2922851C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/50Nitrogen atoms bound to hetero atoms
    • C07D277/52Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA2922851A 2013-09-10 2014-09-09 Sodium channel modulators for the treatment of pain and diabetes Active CA2922851C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876046P 2013-09-10 2013-09-10
US61/876,046 2013-09-10
PCT/US2014/054764 WO2015038533A2 (en) 2013-09-10 2014-09-09 Sodium channel modulators for the treatment of pain and diabetes

Publications (2)

Publication Number Publication Date
CA2922851A1 CA2922851A1 (en) 2015-03-19
CA2922851C true CA2922851C (en) 2023-03-14

Family

ID=52666496

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2922851A Active CA2922851C (en) 2013-09-10 2014-09-09 Sodium channel modulators for the treatment of pain and diabetes

Country Status (18)

Country Link
US (2) US20160221974A1 (enExample)
EP (1) EP3043787B1 (enExample)
JP (1) JP6445565B2 (enExample)
KR (1) KR20160054570A (enExample)
CN (1) CN105611923B (enExample)
AU (1) AU2014318979B2 (enExample)
BR (1) BR112016005271A2 (enExample)
CA (1) CA2922851C (enExample)
ES (1) ES2687598T3 (enExample)
IL (1) IL244506B (enExample)
MX (1) MX2016002881A (enExample)
MY (1) MY181928A (enExample)
PH (1) PH12016500296A1 (enExample)
RU (1) RU2016113156A (enExample)
SG (2) SG11201601367QA (enExample)
UA (1) UA120353C2 (enExample)
WO (1) WO2015038533A2 (enExample)
ZA (1) ZA201702410B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900604A1 (en) * 2013-03-15 2014-09-25 Chromocell Corporation Sodium channel modulators for the treatment of pain
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
WO2016040315A1 (en) * 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
BR112018012327A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem
ES3022639T3 (en) 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
CN105924843A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆
CN105924670A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种电力电缆用耐磨剂
CN106084535A (zh) * 2016-06-02 2016-11-09 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆的制备方法
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
CN106892845B (zh) * 2017-02-28 2018-10-30 四川同晟生物医药有限公司 一种2,4-二氨基丁酸衍生物及其制备方法
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
BR112020024729A2 (pt) 2018-06-13 2021-03-23 Xenon Pharmaceuticals, Inc. compostos de benzenossulfonamida e seu uso como agentes terapêuticos
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
PT1368355E (pt) * 2001-03-14 2006-09-29 Gruenenthal Gmbh Pirazolopirimidinas e tiazolopirimidinas substituidas, como analgesicos
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
MXPA06012613A (es) 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
BRPI0513717A (pt) * 2004-07-23 2008-05-13 Pfizer derivados de piridina
AU2005300150A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
SG170767A1 (en) * 2005-12-23 2011-05-30 Zealand Pharma As Modified lysine-mimetic compounds
AR065194A1 (es) * 2007-02-05 2009-05-20 Xenon Pharmaceuticals Inc Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
JP5463285B2 (ja) 2007-07-13 2014-04-09 アイカジェン, インコーポレイテッド ナトリウムチャネル阻害物質
EA020460B1 (ru) * 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
MX2011012712A (es) 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
US8895608B2 (en) 2010-04-23 2014-11-25 Kineta, Inc. Sulfonamide anti-viral compounds
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
US9096558B2 (en) 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds
ES2533065T3 (es) * 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CN103492575A (zh) 2011-01-18 2014-01-01 安姆根有限公司 NaV1.7敲除小鼠及其用途
TWI478908B (zh) * 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
US9079902B2 (en) 2011-08-17 2015-07-14 Amgen Inc. Heteroaryl sodium channel inhibitors
CA2849505A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
CA2900604A1 (en) * 2013-03-15 2014-09-25 Chromocell Corporation Sodium channel modulators for the treatment of pain
MX2016002974A (es) 2013-09-09 2016-06-02 Peloton Therapeutics Inc Eteres de arilo y sus usos.
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
WO2016040315A1 (en) 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes

Also Published As

Publication number Publication date
SG11201601367QA (en) 2016-03-30
BR112016005271A2 (pt) 2020-05-12
US9458118B2 (en) 2016-10-04
KR20160054570A (ko) 2016-05-16
US20160130239A1 (en) 2016-05-12
JP2016532716A (ja) 2016-10-20
IL244506B (en) 2020-02-27
US20160221974A1 (en) 2016-08-04
SG10201805552PA (en) 2018-08-30
AU2014318979B2 (en) 2019-03-28
CA2922851A1 (en) 2015-03-19
CN105611923B (zh) 2019-08-23
JP6445565B2 (ja) 2018-12-26
WO2015038533A2 (en) 2015-03-19
RU2016113156A (ru) 2017-10-16
AU2014318979A1 (en) 2016-03-03
EP3043787A2 (en) 2016-07-20
PH12016500296A1 (en) 2016-05-16
RU2016113156A3 (enExample) 2018-07-02
EP3043787A4 (en) 2017-02-01
IL244506A0 (en) 2016-04-21
CN105611923A (zh) 2016-05-25
UA120353C2 (uk) 2019-11-25
MY181928A (en) 2021-01-14
MX2016002881A (es) 2016-04-21
ZA201702410B (en) 2019-06-26
ES2687598T3 (es) 2018-10-26
EP3043787B1 (en) 2018-09-05
WO2015038533A3 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
CA2922851C (en) Sodium channel modulators for the treatment of pain and diabetes
US10179781B2 (en) Sodium channel modulators for the treatment of pain
EP2358371B1 (en) P2x3, receptor antagonists for treatment of pain
KR20060130159A (ko) 당뇨병 및 비만증 치료용 글리코겐 인산화효소억제제로서의(3-옥소-3,4-디하이드로-퀴녹살린-2-일-아미노)-벤즈아미드유도체 및 관련 화합물
TW201920135A (zh) 吡唑衍生化合物及其用途
RU2648242C2 (ru) Производное имидазопиридина, используемое для лечения сахарного диабета
US20170304306A1 (en) SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES
WO2006095822A1 (ja) スルホンアミド化合物およびその医薬
HK1224572A1 (en) Sodium channel modulators for the treatment of pain and diabetes
JP2008533122A (ja) 新規なチロシン誘導体
CN116891447A (zh) 一类trpv1拮抗剂、制备方法及其在制备治疗疼痛药物中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190906

EEER Examination request

Effective date: 20190906

EEER Examination request

Effective date: 20190906

EEER Examination request

Effective date: 20190906

EEER Examination request

Effective date: 20190906

EEER Examination request

Effective date: 20190906

EEER Examination request

Effective date: 20190906